GlassScriptPhysician profile
Jian Guan
NPI 1053799304
$2,687.73
in general payments reported to CMS, 2019-2025
38 companies · $685 in 2025
The $685 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $13.73 · 2021: $267 · 2022: $618 · 2023: $679 · 2024: $257 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387 · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,387.27 |
| Education | $233.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $493.40 | 2021-2023 | Retevmo, Jaypirca |
| Takeda Pharmaceuticals U.S.A., INC. | $290.09 | 2022-2025 | Livtencity, Alunbrig |
| Astellas Pharma US INC | $197.32 | 2022-2025 | Cresemba, Padcev, Xospata |
| Novartis Pharmaceuticals Corporation | $148.19 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $142.39 | 2025 | Imjudo, Tagrisso |
| Intercept Pharmaceuticals, INC. | $120.77 | 2019 | |
| Amgen INC. | $109.91 | 2022-2023 | Lumakras |
| Depuy Synthes Sales INC. | $97.73 | 2022 | |
| Rigel Pharmaceuticals, INC. | $83.85 | 2021-2022 | |
| Genzyme Corporation | $68.90 | 2023-2024 | |
| Pfizer INC. | $68.90 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $63.29 | 2025 | Onivyde |
| Janssen Biotech, INC. | $63.02 | 2024-2025 | Rybrevant, Akeega, Erleada |
| Daiichi Sankyo INC. | $55.24 | 2024-2025 | Enhertu, Vanflyta |
| Octapharma USA, INC. | $54.28 | 2024 | Balfaxar |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jian Guan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.